Get the Stockscreener App
2.17
1.36%
-0.03
After Hours:
2.04
-0.13
-5.99%
Calcimedica Inc stock is traded at $2.17, with a volume of 94,117.
It is down -1.36% in the last 24 hours and up +172.96% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
See More
Previous Close:
$2.20
Open:
$2.13
24h Volume:
94,117
Relative Volume:
0.07
Market Cap:
$66.70M
Revenue:
-
Net Income/Loss:
$-19.54M
P/E Ratio:
-1.6602
EPS:
-1.3071
Net Cash Flow:
$-21.18M
1W Performance:
+367.27%
1M Performance:
+172.96%
6M Performance:
+247.76%
1Y Performance:
-31.55%
1-Day Range:
$2.09
$2.25
1-Week Range:
$2.00
$2.4727
52-Week Range:
$0.44
$7.20
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
2.17 | 17.93M | 0 | -19.54M | -21.18M | -1.3071 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Calcimedica Inc Stock (CALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
Calcimedica Inc Stock (CALC) Latest News
CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk - TipRanks
CalciMedica (NASDAQ: CALC) fixes one Nasdaq warning but faces a $1 price deadline - Stock Titan
Stonepine Capital Management Expands CalciMedica Stake in Bold Contrarian Move - GuruFocus
CalciMedica To Carry Out 1-for-5 Reverse Stock Split On August 31st, 2026 - Moomoo
CalciMedica executes 1-for-5 reverse stock split By Investing.com - Investing.com South Africa
CalciMedica executes 1-for-5 reverse stock split - Investing.com
CalciMedica Inc (CALC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CalciMedica (CALC) Quarter in Focus: The Available Earnings Metric Delivers a Beat; Closing Move: Shares Move Higher 5.68% for the Current SessionEarnings Call Transcript - vinanet.vn
Stonepine takes CalciMedica (CALC) stake via capped warrants - Stock Titan
Alafi Capital updates CalciMedica (NASDAQ: CALC) stake after multimillion-warrant grant - stocktitan.net
CalciMedica (CALC) grants director 10,000 stock options through 2036 - Stock Titan
CalciMedica (NASDAQ: CALC) awards director 10,000 options at $0.61 - Stock Titan
CalciMedica (CALC) grants director 10,000 stock options at $0.61 - Stock Titan
CalciMedica (CALC) director granted 2.9M-share warrants with 9.99% cap - Stock Titan
CalciMedica (NASDAQ: CALC) grants FDA-linked warrants capped at 19.99% stake - Stock Titan
CalciMedica (NASDAQ: CALC) CEO granted new stock warrants - Stock Titan
CalciMedica (NASDAQ: CALC) has 9.99% holder blocked from using more warrants - Stock Titan
CalciMedica (CALC) Financial Update: EPS Lands Above Forecast in the Current Update; The Stock Ends Down 4.88% in the Current UpdateProfit Inflection Point - vinanet.vn
ARMISTICE CAPITAL, LLC Acquires Significant Stake in CalciMedica Inc (CALC) - GuruFocus
CalciMedica Shareholders Approve Reverse Stock Split - Minichart
CalciMedica Shareholders Approve Key Equity and Governance Changes - TipRanks
CalciMedica (NASDAQ: CALC) holders back reverse split and warrant deals - Stock Titan
Guggenheim initiates CalciMedica stock with buy rating on drug potential - Investing.com
Guggenheim initiates CalciMedica stock coverage with buy rating By Investing.com - Investing.com India
CalciMedica (CALC) Edges Higher by 2.71% as Shares Consolidate Between $0.65 and $0.71TRIN Signal - dars.gov.et
Woodline Partners discloses 8.1% CalciMedica (CALC) stake and sole voting power - Stock Titan
Armistice Capital (CALC) discloses 3.41M-share, 9.99% holding in CalciMedica - Stock Titan
CALC Q1 2026 Earnings: EPS of $0.30 Crushes Estimates, Stock Advances 6%Revenue Miss Report - vinanet.vn
CALC Q1 2026 Earnings: EPS Swings to Profit With 205.04% SurpriseEarnings Sentiment Score - vinanet.vn
CalciMedica shares see H.C. Wainwright neutral rating reiterated - Investing.com
CalciMedica shares see H.C. Wainwright neutral rating reiterated By Investing.com - Investing.com Canada
Price to book forward of CalciMedica, Inc. – NASDAQ:CALC - TradingView
Price to book forward of CalciMedica, Inc. – BOATS:CALC - tradingview.com
Price to sales forward of CalciMedica, Inc. – NASDAQ:CALC - tradingview.com
Price to sales forward of CalciMedica, Inc. – BOATS:CALC - TradingView
CalciMedica Inc (CALC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K CalciMedica Inc For: 11 August By Investing.com - Investing.com UK
CalciMedica, Inc. 2Q 2026: Net loss $7.7M, EPS $(0.45) — 10-Q Summary - TradingView
CalciMedica (CALC) cuts expenses, raises $15M but flags going concern risk - Stock Titan
CalciMedica Releases Q2 2026 Financial Results - AlphaStreet
CalciMedica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss - Yahoo Finance
CalciMedica Secures Up To $49 Million Private Placement To Advance Pulmonary Hypertension Pipeline - Minichart
CalciMedica Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CalciMedica Q2 FY26 net loss widens to $7.65 million - Bitget
CalciMedica stock gains 6% despite earnings miss on pulmonary trial By Investing.com - Investing.com South Africa
CalciMedica stock gains 6% despite earnings miss on pulmonary trial - Investing.com
CalciMedica reports Q2 2026 results: $18.6M cash, net loss $7.7M; financing to fund PH programs - TradingView
CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates - Moomoo
CalciMedica Inc (CALC) Stock News Today - TradingKey
CalciMedica Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Calcimedica Inc Stock (CALC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 18 '25 |
Buy |
3.07 |
2,500 |
7,675 |
84,150 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 15 '25 |
Buy |
2.68 |
3,400 |
9,105 |
81,650 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 12 '25 |
Buy |
3.12 |
5,000 |
15,600 |
78,250 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Sep 09 '25 |
Buy |
3.15 |
2,343 |
7,378 |
73,250 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):